History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to monoclonal antibodies.
No history of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components;
No history of severe hypersensitivity to a monoclonal antibody
History of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody.
Treatment with a monoclonal antibody within 30 days prior to Cycle 1, Day 1
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy
Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate within 4 weeks before first infusion
A history of hypersensitivity to other humanized monoclonal antibodies.
History of allergy to study drug components or history of severe hypersensitivity reaction of any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)
History of severe hypersensitivity reactions to other monoclonal antibodies.
Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
Patient has history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
Has had a severe hypersensitivity reaction to treatment with another mAb
Severe hypersensitivity to other monoclonal antibodies (mAbs).
Previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
Previous severe hypersensitivity reaction to treatment with another monoclonal antibody.
Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody/components of the study treatment(s).
Monoclonal antibody or antibody-drug conjugate (ADC) therapy within 3 weeks prior to Day 1 of Cycle 1.
Any history of a severe hypersensitivity reaction to any monoclonal antibody
Significant prior infusion reaction to monoclonal antibodies that required treatment with systemic steroids
History of severe hypersensitivity reactions to other monoclonal antibodies
Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody (mAb).
History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
Known severe hypersensitivity reactions to monoclonal antibodies; any history of anaphylaxis or uncontrolled asthma.
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reactions to monoclonal antibodies.
Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
Patients with a history of allergy to study drug components or history of a severe hypersensitivity reaction to any monoclonal antibody
Previous severe hypersensitivity reaction to another monoclonal antibody, such as colitis or pneumonitis requiring treatment with steroids, or has a history of interstitial lung disease.
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
Patients with a history severe (>= grade 3) hypersensitivity reaction to a monoclonal antibody are ineligible
EXCLUSION CRITERIA FOR STRATUM C: Patients with a history severe (>= grade 3) hypersensitivity reaction to a monoclonal antibody are ineligible
History of hypersensitivity reaction to human or mouse antibody products
No prior severe infusion reaction to a monoclonal antibody
No monoclonal antibody within 3 months unless evidence of disease progression
No history of severe reactions to fluorouracil (5-FU), irinotecan hydrochloride (irinotecan), or a monoclonal antibody
Known severe (grade >= 3 NCI-CTCAE) hypersensitivity reactions to monoclonal antibodies, or history of anaphylaxis.
History of severe hypersensitivity reaction to treatment with another monoclonal antibody
History of Grade 4 anaphylactic reaction to monoclonal antibody therapy.
History of severe hypersensitivity reaction to any monoclonal antibody.
No prior severe infusion reaction to cetuximab or a monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody.
History of severe hypersensitivity reaction to another monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal antibodies
Any history of a sever hypersensitivity reaction to any monoclonal antibody
Any history of a sever hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal antibodies
History of anaphylactic reaction to monoclonal antibody therapy
Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody (mAb) therapy
History of severe hypersensitivity reaction to any monoclonal antibody.
History of severe hypersensitivity reaction to any monoclonal antibody including pembrolizumab
Severe hypersensitivity reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug component
History of severe hypersensitivity reactions to other monoclonal antibodies
History of anaphylactic reaction to monoclonal antibody therapy
History of hypersensitivity reaction to human or mouse antibody products
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to Cremaphor EL
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reaction to any monoclonal antibody and/or to study drug components
History of severe hypersensitivity reaction to any monoclonal antibody
Patients who have received monoclonal anti-cancer antibody within 4 weeks of first dose of study drugs
History of hypersensitivity reaction to human or mouse antibody products
Patients with allergies or adverse drug reactions to the following are not eligible:\r\n* History of allergy to study drug components;\r\n* History of severe hypersensitivity reaction to any monoclonal antibody
Allergies and adverse drug reaction; a) history of allergy to study drug components; b) history of severe hypersensitivity reaction to any monoclonal antibody
Prior hypersensitivity to monoclonal antibodies
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody or study drug components
Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start.
History of severe hypersensitivity reaction to any monoclonal antibody
Known severe hypersensitivity reactions to monoclonal antibodies or carboplatin >= grade 3, any history of anaphylaxis, or uncontrolled asthma
History of severe hypersensitivity reaction to any monoclonal antibody
Previous severe hypersensitivity reaction to another monoclonal antibody
Prior use of any monoclonal antibody within 3 months of the start of Cycle 1
Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal Antibodies
History of allergy or adverse drug reaction to the study drug components (nivolumab, dabrafenib, or trametinib) or drugs of similar chemical or biologic composition; patients with a history of severe hypersensitivity reaction to any monoclonal antibody should also be excluded
History of hypersensitivity reaction to human or mouse antibody products
History of grade 3 or above hypersensitivity reactions to other monoclonal antibodies
Patients with history of hypersensitivity to monoclonal antibodies
At least three (3) half-lives of the antibody must have elapsed since the last dose of a monoclonal antibody
Allergies and adverse drug reaction to the following: history of allergy to study drug components; history of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to other monoclonal antibodies
Prior severe infusion reaction to a monoclonal antibody
Known severe (grade 3 or 4) infusion-related allergy or hypersensitivity to any monoclonal antibody
Monoclonal antibody(ies) (At least 3 half-lives since the last dose of any monoclonal antibody prior to first dose of tazemetostat)
Known allergic reaction to a prior monoclonal antibody therapy or have any documented Anti-Drug Antibody (ADA) response
Allergies and adverse drug reaction\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody
Prior therapy with monoclonal antibody (mAb) against CTLA-4
History of severe hypersensitivity reaction to any monoclonal antibody
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: History of severe hypersensitivity reaction to any monoclonal antibody
At least 7 days must have elapsed after the last of a biologic agent that is not a monoclonal antibody, to be enrolled on this study
No history of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
At least 3 half-lives of the antibody after the last dose of a monoclonal antibody.
History of allergy to study drug components or history of severe hypersensitivity reaction of any monoclonal antibody
Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose of a monoclonal antibody; specifically for bevacizumab 36 days after the last dose
Any allergic reaction to a previously administered monoclonal antibody or other therapeutic protein
Severe hypersensitivity reaction to treatment with another monoclonal antibody
Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) or interferon-alpha2b (IFN-a2b)
Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously exposed to rituximab or other monoclonal antibody therapy
Subject has prior severe allergic reaction or intolerance to a monoclonal antibody, including humanized or chimeric antibodies.
History of severe hypersensitivity to monoclonal antibodies (mAbs).
Hypersensitivity to HTI-1066 or sensitivity to humanized monoclonal antibody products
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
History of severe hypersensitivity reaction to any monoclonal antibody
Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs.
History of grade IV anaphylactic reaction to monoclonal antibody therapy
History of severe hypersensitivity reaction with biologics therapy (monoclonal antibodies)
Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
Monoclonal antibody within 28 days prior to day 1 of protocol therapy
Known hypersensitivity to monoclonal antibodies
History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibodies (e.g., Enbrel which is the Fc portion of an antibody or Lucentis which is a Fab)
Patients with a history of severe (grade >= 3) hypersensitivity reaction to a monoclonal antibody are ineligible
History of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may pose an increased risk of a serious infusion reaction.
Any of the following:\r\n* Prior anti-cancer monoclonal antibody (mAb) =< 4 weeks prior to registration
Patients who have had a prior severe infusion reaction to a monoclonal antibody are not eligible
Any history of a severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
No prior severe infusion reaction to a monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose of a monoclonal antibody
Previous monoclonal antibody (mAb) or other treatment specifically directed against CD19; history of serious allergy or reaction to any component of the MEDI-551 formulation that would prevent administration
Monoclonal antibody therapy administered within 30 days of the agent prior to apheresis
Prior allergic reaction to the study drugs involved in this protocol or to a monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
Prior severe infusion reaction to a monoclonal antibody
No anti-CD25 monoclonal antibody therapy within 12 weeks of enrollment
Monoclonal antibody (ies) (At least 3 half-lives since the last dose of any monoclonal antibody prior to first dose of tazemetostat)
Allergies and Adverse Drug Reaction a) History of allergy to study drug components b) History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal antibodies.
Prior therapy with any anti CD137 monoclonal antibody.
Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
Monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks
At least 4 weeks from end of monoclonal antibody therapy
Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).
Prior monoclonal antibody treatment within 4 weeks before study Day 1
Monoclonal antibody (ies) At least 28 days
History of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs)
Allergies and adverse drug reaction\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before Cycle 1, Day 1
History of severe hypersensitivity reaction to taxanes
History of severe hypersensitivity reaction to any monoclonal antibody
Anti-CD20 monoclonal antibody therapy within the last 3 months, or absence of circulating B cells
Received prior monoclonal antibody (mAb) within 4 weeks prior to study.
Prior severe infusion reaction to a monoclonal antibody
Severe hypersensitivity reaction to treatment with another monoclonal antibody
Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)
Patients who previously had a severe reaction to treatment with a human antibody.
History of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodies
History of severe infusion reactions to monoclonal antibody therapy
History of hypersensitivity reaction to human or mouse antibody products
Patients must not have a history of a grade 4 anaphylactic reaction to monoclonal antibody therapy or known hypersensitivity reactions to drugs formulated with polysorbate 90
Participant has previous severe hypersensitivity reaction to another monoclonal antibody (mAb).
History of severe hypersensitivity reaction to any monoclonal antibody
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ?3), any history of anaphylaxis.
Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
History of severe hypersensitivity reactions to other monoclonal antibodies
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Patient has a known hypersensitivity to cetuximab or any other monoclonal antibody
No prior severe infusion reaction to cetuximab or a monoclonal antibody
Patient has had a prior monoclonal antibody for treatment of MCC
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction (>= grade 3) to docetaxel
Previous serious hypersensitivity reaction to monoclonal antibodies. (Determination of \serious\ hypersensitivity reaction is at the investigator's discretion.)
Monoclonal antibodies: ?21 days or 3 half-lives (whichever is shorter) of the antibody must have elapsed after the last dose of a monoclonal antibody (including checkpoint inhibitors). Toxicity related to prior antibody therapy must be recovered to Grade ?1
History of hypersensitivity reaction to human or mouse antibody products
History of severe hypersensitivity reaction to any monoclonal antibody
Has a history of a severe hypersensitivity reaction to treatment with another monoclonal antibody
Treatment with anti-CD20 monoclonal antibody within 3 months of randomization
At least 3 half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (i.e. gemtuzumab = 36 days)
Monoclonal antibodies within 28 days
Severe hypersensitivity reaction to treatment with another monoclonal antibody, known or suspected hypersensitivity to study drugs or any component of their formulation.
History of severe hypersensitivity reactions or immune related adverse events to other monoclonal antibodies
Has had a severe hypersensitivity reaction to treatment with another monoclonal antibody
Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (ie. Rituximab=66 days, Epratuzumab=69 days)
History of allergy to study drug components or of severe hypersensitivity reaction to any monoclonal antibody
Monoclonal antibody therapy < 30 days from study enrollment
History of severe reaction to prior monoclonal antibody therapy (defined as a Grade 4 event and/or requiring permanent discontinuation)
A history of a severe hypersensitivity reaction to ipilimumab or dabrafenib
Monoclonal antibody therapy less than 1 month
Monoclonal antibodies: at least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody
History of severe infusion reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
Treatment with chemotherapy or monoclonal antibody within 28 days prior to entering the study
Treatment with chemotherapy or monoclonal antibody during the time of participation in this trial
Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
Prior hypersensitivity to monoclonal antibodies
Less than four weeks since last monoclonal antibody-containing therapy
Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of the study drugs
History of hypersensitivity reaction to human or mouse antibody products
History of a significant allergic reaction attributed to humanized or human monoclonal antibody therapy
History of severe hypersensitivity reaction to polysorbate 80
Known hypersensitivity to afatinib, monoclonal antibody
Prior severe infusion-related reaction to a monoclonal antibody
Prior severe infusion reaction to a monoclonal antibody
History of hypersensitivity reaction to human or mouse antibody products
A history of a severe hypersensitivity reaction to nab-paclitaxel
Prior monoclonal antibody: participants having received prior in vivo monoclonal anti-GD2 antibodies for biologic therapy or for tumor imaging AND experienced a severe allergic reaction while receiving prior anti-GD2 therapy; (Note: participants who have received previous therapy with anti-GD2 monoclonal antibodies are eligible for this study, provided they did not experience a severe allergic reaction with the antibody)
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity reaction to any monoclonal antibody
History of severe hypersensitivity to monoclonal antibodies.
History of severe hypersensitivity to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.
At least 14 days must have elapsed since the completion of therapy with a monoclonal antibody
History of severe hypersensitivity reactions to other monoclonal antibodies.
History of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody
Patients with a history of clinically significant cutaneous drug reaction, hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to the medication used in the study
History of infusion reactions to monoclonal antibody therapies
History of infusion reactions to panitumumab or other monoclonal antibody therapies
History of infusion reactions monoclonal antibody therapies
History of infusion reactions to cetuximab or other monoclonal antibody therapies
History of infusion reactions to cetuximab or other monoclonal antibody therapies
History of severe hypersensitivity reactions to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
History of infusion reactions to cetuximab or other monoclonal antibody therapies
History of severe hypersensitivity reactions to other monoclonal antibodies.
Monoclonal antibody: ?3 half-lives of antibody since last admin.
History of severe hypersensitivity reaction to other monoclonal antibodies
Known intolerance to CD20 monoclonal antibody therapy
History of severe hypersensitivity reaction to any monoclonal antibody
